Reasons Women at Elevated Risk of Breast Cancer Refuse Breast MR Imaging Screening: ACRIN 6666

Wendie A. Berg, MD, PhD
Jeffrey D. Blume, PhD
Amanda M. Adams, MPH
Roberta A. Jong, MD
Richard G. Barr, MD, PhD
Daniel E. Lehrer, MD
Etta D. Pisano, MD
W. Phil Evans III, MD
Mary C. Mahoney, MD
Linda Hovanessian Larsen, MD
Glenna J. Gabrielli, BS
Ellen B. Mendelson, MD

1 From American Radiology Services, Johns Hopkins Green Spring, 10755 Falls Rd, Suite 440, Lutherville, MD 21093 (W.A.B.); Center for Statistical Sciences, Brown University, Providence, RI (J.D.B., A.M.A.); Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada (R.A.J.); Radiology Consultants/Forum Health, Youngstown, Ohio (R.G.B.); Centro de Estudios Radiológicos Integrales de la Mamá, Buenos Aires, Argentina (D.E.L.); University of North Carolina, Chapel Hill, NC (E.D.P.); University of Texas Southwestern Medical Center, Dallas, Tex (W.P.E.); University of Cincinnati Medical Center, Cincinnati, Ohio (M.C.M.); Keck School of Medicine, University of Southern California, Los Angeles, Calif (E.B.M.); American College of Radiology, Philadelphia, Pa (E.G.); and Feinberg School of Medicine, Northwestern University, Chicago, Ill (E.B.M.).

2 From the 2008 RSNA Annual Meeting. Received May 30, 2009; revision requested July 2; revision received July 28; accepted August 4; final version accepted August 5. Supported by grants from the Avion Foundation and the National Cancer Institute (grants U01 CA079778, U01 CA09808). Address correspondence to W.A.B. (e-mail: wendieberg@gmail.com).

Purpose: To determine reasons for nonparticipation in a trial of supplemental screening with magnetic resonance (MR) imaging after mammography and ultrasonography (US).

Materials and Methods: Women (n = 2809) at elevated risk of breast cancer were enrolled in the American College of Radiology Imaging Network 6666 US Screening Protocol at 21 institutions. Fourteen institutions met technical and experience requirements for this institutional review board–approved, HIPAA-compliant substudy of supplemental screening with MR imaging. Those women who had completed 0-, 12-, and 24-month screenings with mammography combined with US were considered for a single contrast material–enhanced MR examination within 8 weeks after completing the 24-month mammography-US screening. A total of 1393 women had complete MR substudy registration data: 378 of them were ineligible for the study, and 1215 had analyzable data. Reasons for nonparticipation were determined. Demographic data were compared between study participants and nonparticipants.

Results: Of 1215 women with analyzable data, 703 (57.9%), with a mean age of 54.8 years, were enrolled in the MR substudy and 512 (42.1%) declined participation. Women with a 25% or greater lifetime risk of breast cancer were more likely to participate (odds ratio, 1.53; 95% confidence interval: 1.10, 2.12). Of 512 nonparticipants, 130 (25.4%) refused owing to claustrophobia; 93 (18.2%), owing to time constraints; 62 (12.1%), owing to financial concerns; 47 (9.2%), because their physician would not provide a referral and/or did not believe MR imaging was indicated; 40 (7.8%), because they were not interested; 39 (7.6%), because they were medically intolerant to MR imaging; 27 (5.3%), owing to additional biopsy or other procedures that might be required subsequently; 21 (4.1%), owing to MR imaging scheduling constraints; 11 (2.2%), because of the travel required; seven (1.4%), owing to gadolinium-related risks or allergies; and six (1.2%), for unknown reasons.

Conclusion: Of 1215 women with elevated breast cancer risk who could, according to protocol guidelines, undergo breast MR imaging, only 57.9% agreed to participate.

© RSNA, 2010
**Contrast material–enhanced magnetic resonance (MR) imaging can depict many node-negative invasive breast cancers and ductal carcinomas in situ that are not seen at mammography or ultrasonography (US) (1). Although mammography remains the mainstay examination for breast cancer screening, it has reduced sensitivity when the breast parenchyma is dense (2). Women who are at high risk for breast cancer because they are known or suspected to have *BRCA1* or *BRCA2* mutations of known penetrance often begin undergoing screening when they are aged 25–30 years (3), when the breast tissue is more often dense. Mammography is particularly ineffective in depicting early breast cancer in *BRCA1* carriers (4). In 2007, the American Cancer Society (ACS) recommended annual supplemental screening with MR imaging in high-risk women (3).

In women at intermediate breast cancer risk, supplemental screening with MR imaging may or may not be warranted (3). This group includes women with a personal history of breast cancer, women with a history of previous lobular carcinoma in situ or atypical hyperplasia, women with a family history of intermediate risk (lifetime risk of 15%–20%), and those with dense breasts (5). The use of supplemental screening US has been advocated among women who are at high risk but are unable to tolerate MR imaging and those who are at intermediate risk (1).

The American College of Radiology Imaging Network (ACRIN) 6666 Protocol was designed for the evaluation of supplemental breast US screening in women with elevated risk of breast cancer and at least heterogeneously dense breasts (5). A total of 2809 women were enrolled in the main study, and all of them met the criteria for at least intermediate risk (6), although the definitions of risk were slightly different from those of the ACS (3). In the third round of annual screening in ACRIN 6666, eligible participants were offered a single contrast-enhanced breast MR imaging screening examination. We were surprised at the relatively low rates of participation in this MR imaging substudy that we observed initially. Thus, the purpose of this study was to determine the reasons for nonparticipation in a trial of supplemental screening with MR imaging after mammography combined with US.

### Materials and Methods

**Study sites** were required to meet technical and experience requirements for the MR imaging substudy (7). Women invited to undergo MR imaging screening were actively enrolled participants in the original ACRIN 6666 Protocol (7) and needed to have completed three rounds (at 0, 12, and 24 months) of annual screening with mammography and US before the date of MR imaging. Women were approached for participation in the MR imaging sub-study shortly before, at the time of, or shortly after they had completed the third round (24-month) of annual screening with mammography and US. The original ACRIN 6666 Protocol and the MR imaging substudy had been approved by the Cancer Therapy Experimental Protocols Committee of the National Cancer Institute, ACRIN, and the site institutional review boards. Study and patient consent protocols were Health Insurance Portability and Accountability Act compliant. Women were approached for participation from August 1, 2006, through April 21, 2008.

At most participating centers, women were told that their insurance provider would be billed if their physician agreed to provide a referral and that ACRIN study funding would cover any costs for MR imaging that were not covered by insurance. For the Canadian and Argentine sites, at which there was neither insurance nor governmental coverage for MR imaging screening, ACRIN contracted to pay $500 for each MR screening examination. For two American sites, hospital or university guidelines prohibited insurance billing for any examination that was part of a research protocol, and ACRIN contracted to pay these sites a maximum of $300 per MR screening examination. The amount of $300 was derived from actual costs and had been used in prior ACRIN protocols. Participants were

### Implications for Patient Care

- In prior research to evaluate tolerance for breast MR imaging examinations, patient acceptance of this examination was probably overestimated, as the data of only those women who underwent MR imaging were evaluated; rates of claustrophobia in particular have probably been underestimated in prior reports.
- Our results may help to inform public health agencies that recommend breast MR imaging screening in subgroups of women at increased risk of breast cancer, as there appear to be large groups of women in whom alternative screening strategies should be considered.

### Advances in Knowledge

- Of 1215 women at elevated risk of breast cancer who were offered contrast-enhanced MR imaging screening, 703 (57.9%) agreed, and 627 (51.6%) of the women asked to participate actually completed the screening according to the study protocol.
- Claustrophobia was the most common reason (in 130 [25.4%] of 512 women) given for nonparticipation.
required to agree specifically to undergo follow-up MR imaging at 6 months; undergo MR imaging–guided vacuum-assisted biopsy or US-guided core-needle biopsy (billed to insurance), if needed, on the basis of the MR results; and provide clinical follow-up information 11–14 months after completing the MR screening examination. The MR examination was to be scheduled, when possible, for 7–14 days after the onset of menses in premenopausal women and to be completed within 8 weeks—in no case more than 91 days—after the 24-month screening mammographic and US examinations.

If a woman had any contraindications to MR imaging, this was recorded as her reason for not participating. These contraindications included pacemaker, aneurysm clip, or other implanted metallic device; lack of intravenous access; weight of more than 300 pounds; physical inability to tolerate positioning in the MR imaging unit; and impaired renal function as indicated by an estimated glomerular filtration rate of less than 30 mL/min/1.73 m² and/or a dialysis regimen (indicating a risk for nephrogenic systemic fibrosis [NSF]). Midway through the study recruitment period, on May 23, 2007, the Food and Drug Administration requested manufacturers to include a black box warning for all gadolinium-based contrast agents. This information, including disclosure of the risk of death, was immediately added to the consent forms for this study. Claustrophobia that could not be controlled with sedative or anxiolytic premedication under the physician’s orders was recorded separately.

Statistical Analyses

If the patient was eligible for but did not participate in the MR imaging substudy, the primary reason for nonparticipation was recorded after the patient was interviewed by the site research assistant and summarized on a form listing the possible reasons. “Other” comments were used if the response did not fit any existing category; these comments were later reviewed, and additional categories were created as needed. The demographic data on the MR substudy participants were compared with those of participants in the original ACRIN 6666 Protocol. Our statistical methods were primarily descriptive. Two-sample t tests and χ² tests of association (Stata, version 10, Stata, College Station, Tex; SAS 9.1.3, SAS Institute, Cary, NC) were used to evaluate differences in various characteristics between the groups when necessary. However, to avoid reporting a large number of univariate comparisons that may or may not have been generalizable (because of confounding and effect modification), we modeled the probability of participation as a function of these characteristics in a logistic regression model.

The following specific characteristics were evaluated: ethnicity, lifetime risk of breast cancer according to Gail et al (8) or Claus et al (9) model, 5-year risk of breast cancer according to Gail et al model, personal history of breast cancer, and prior mammography within 14 months of study entry. We used a random-effects model for site to adjust for institution-to-institution variability. We evaluated the fits of these logistic models by examining the likelihood and using the C-statistic, and a best model was selected. P ≤ .05 was considered to indicate significance. We examined patient participation rates over time, including the periods before and after the March 28, 2007, publication of the ACS guidelines recommending MR imaging (3) and the May 23, 2007, Food and Drug Administration announcement regarding the risk of NSF.

Results

Of 21 sites included in the original ACRIN 6666 Protocol, 14 met technical and experience requirements for the MR imaging substudy. Of 2725 eligible participants enrolled in the main ACRIN 6666 Protocol, 2023 (74.2%) were at a site that was approved for MR imaging according to protocol guidelines. Some sites did not immediately meet all requirements, including institutional review board approval; thus, 428 women could not be registered for the MR imaging substudy. In addition, two women withdrew their consent prior to study registration. Thus, the remaining 1593 women could be approached for participation in the substudy (Figure). Three hundred seventy-eight women were ineligible; nearly half of these patients were not eligible because they did not undergo the 24-month screening mammography and US exams by the cutoff date for entry into the MR imaging substudy. Of the remaining 1215 women, 703 (37.9%) agreed to participate and 312 (42.1%) did not.

Demographic information on the women who did and did not agree to participate in the MR substudy and on the overall population of women who were eligible for the main ACRIN 6666 Protocol are detailed in Table 1. The median age of the patients in all three groups was the same, 55 years, with ages ranging from 25 to 91 years among the women who enrolled in the main protocol 2 years earlier and ages ranging from 26 to 87 years among the women who declined to enroll in the MR substudy. The results of the random-effects logistic regression model are detailed in Table 2. The Hispanic or Latino women enrolled in the main ACRIN 6666 Protocol tended to be less likely to participate: 96 agreed to participate, and 94 refused, representing 13.7% of the 703 substudy participants and 18.4% of the 512 nonparticipants (odds ratio, 0.51 [95% confidence interval: 0.24, 1.10]). Women with the greatest lifetime risk (≥25% risk according to Gail et al [8] or Claus et al [9] model) were more likely to participate in the MR substudy: 155 agreed to participate, and 78 declined, representing 22.0% of those who agreed to participate versus 15.2% of those who did not (odds ratio, 1.53 [95% confidence interval: 1.10, 2.12]).

The reasons the 512 women declined to participate in the MR substudy are detailed in Table 3. The most common reasons were claustrophobia, with 130 (25.4%) women citing this reason for declining, and time constraints or other priorities, with 93 (18.2%) women stating that they declined for this reason.

Of the 703 women who initially agreed to participate in the MR substudy, nine withdrew their consent before undergoing the MR examination. Another 46 women did not actually
undergo MR imaging because they changed their mind or did not present for the appointment (n = 18), they encountered problems with scheduling the MR examination (n = 16), they had financial concerns (n = 7), their physician would not provide a referral (n = 3), or the distance to travel for the MR examination was prohibitive (n = 2).

Among the remaining 648 participants who were actually placed in the MR unit, 13 (2.0%) were unable to tolerate the examination, and for three of these women, this was owing to claustrophobia (Table 3). For another seven participants, the resultant MR images were deemed unreadable and the patient refused to repeat the examination. For one patient, MR imaging was completed more than 91 days after the 24-month mammography and US examinations. As such, 627 women—51.6% of the 1215 eligible women asked to participate—successfully completed the MR screening examination within the specified period. Participation rates varied by site and ranged from 29% to 81% among the sites that were active for more than 1 year. At one site, which became qualified to offer MR imaging during the last 2 months of study enrollment, only two (8%) of 24 women asked to participate were able to enroll in the study.

Among the 627 women who completed the MR imaging examination, the examinations for 238 (38%) of them were paid for completely by ACRIN without billing insurance. For the other 389 women, insurance was initially billed, resulting in no (n = 63) or partial (n = 124) payment.

When we evaluated the reasons for refusing to participate in the MR substudy cited before and after publication of the ACS recommendations for MR imaging screening—and the surrounding publicity—among the women at high risk for breast cancer (3), we noted a decrease in the rate of physicians not providing referrals or not believing MR imaging was indicated: from 20 (13.7%) of 146 cases before the ACS recommendations to 27 (7.4%) of 366 cases after March 28, 2007 (P < .03). However, the rates of reported claustrophobia increased over time: from 28 (19.2%) of

Table 1 (continues)
However, guided breast interventional procedures services did not perform MR imaging–of practices with MR imaging screening practices among surveyed members imaging was offered at 64% of respond- ing practices in 2006 in the United States, breast MR imaging is increasingly becoming available in South America, Canada, and much less available in the United States, Western Europe, and Asia.

As a screening test to be practical, a screening test must be widespread, well tolerated, and cost-effective. Breast MR imaging screening is increasingly becoming available and being used in the United States and Western Europe but is less available in Canada and much less available in South America and Asia. In 2006 in the United States, breast MR imaging was offered at 64% of responding practices among surveyed members of the Society of Breast Imaging, but 31% of practices with MR imaging screening services did not perform MR imaging–guided breast interventional procedures (10). In our protocol, only 14 (70%) of 20 active ACRIN 6666 sites met the technical and experience requirements to perform breast MR imaging, and participation was postponed at two sites until at least three MR imaging–guided biopsies had been completed at each facility.

Table 1 (continued)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Enrolled in and Eligible for Main Study (n = 2725)</th>
<th>Agreed to Enroll in MR Substudy (n = 703)*</th>
<th>Declined to Enroll in MR Substudy (n = 512)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aromatase inhibitor</td>
<td>142 (5.21)</td>
<td>31 (4.41)</td>
<td>19 (3.71)</td>
</tr>
<tr>
<td>Bra-ssiere cup size</td>
<td>A</td>
<td>B</td>
<td>C</td>
</tr>
<tr>
<td></td>
<td>440 (16.48)</td>
<td>104 (14.79)</td>
<td>89 (17.38)</td>
</tr>
<tr>
<td></td>
<td>983 (36.07)</td>
<td>267 (37.98)</td>
<td>188 (36.72)</td>
</tr>
<tr>
<td></td>
<td>850 (31.41)</td>
<td>224 (31.86)</td>
<td>155 (30.27)</td>
</tr>
<tr>
<td></td>
<td>312 (11.45)</td>
<td>75 (10.67)</td>
<td>59 (11.52)</td>
</tr>
<tr>
<td></td>
<td>91 (3.34)</td>
<td>25 (3.56)</td>
<td>13 (2.54)</td>
</tr>
<tr>
<td></td>
<td>54 (1.25)††</td>
<td>8 (1.14)</td>
<td>8 (1.56)</td>
</tr>
</tbody>
</table>

Note.—Unless otherwise noted, data are numbers of patients, with percentages in parentheses.

* As detailed in the Figure, registration for the MR imaging substudy was completed for a total of 1215 women, 703 of whom agreed to participate and 512 of whom declined to participate.

† Numbers in parentheses are ranges.

§ Numbers in parentheses are standard deviations.

1 The 86 Hispanic or Latino participants who agreed to participate in the MR substudy and the 79 Hispanic or Latino participants who declined to participate were enrolled at Centro de Estudios Radiológicos Integrales de la Mama, Buenos Aires, Argentina.

2 Some data listed for primary eligible risk factor vary slightly from those originally reported (6) because the Gail model risk had been re- ported as the eligible risk factor but should not have been calculated at all for a few participants as the woman either was younger than 35 years or had a history of lobular carcinoma in situ (LCIS). ADH = atypical ductal hyperplasia, ALH = atypical lobular hyperplasia.

3 Number of months before study entry at which mammography was performed.

4 ** HRT = hormone replacement therapy.

5 Includes seven cases with missing brassiere cup size.

146 cases to 102 (27.9%) of 366 cases (P = .04). Other rates did not change significantly over time. Revision of the consent form in late May 2007 to include information regarding the risk of death from NSF did not significantly affect the rate of refusals due to concerns about gadolinium reactions (three of 199 cases—0.5% of the women who were actually placed in the MR unit—were due to claustrophobia, similar to the 1.3% rate reported by Eshel et al (12).

Our study provided us with the unusual opportunity to record information regarding women who decline to undergo breast MR examinations. The rate of women reporting claustrophobia as the reason for declining (130 [25.4%] of 512) was very high in our series. In a Netherlands MR imaging screening study (13), lying in the magnet bore was the aspect of breast MR imaging most frequently reported (by 21% of those surveyed) as rather to extremely uncomfortable. Despite this, 44% of women in the Netherlands cohort preferred MR imaging for screening compared with 14% who preferred mammography. This was due in part to the higher percentage of women who reported that they would feel “completely reassured” by a favorable MR imaging result (64.4%) compared with the percentage of women who reportedly would be completely reassured by a favorable mammographic result (40.1%).

Higher rates of claustrophobia have been reported among middle-aged women compared with the rates reported among other demographic groups (14), and a correlation with higher education levels and higher socioeconomic status has been reported (15). Although hypnosis (16) and anxiolytic agents such as lorazepam or diazepam can be used effectively to reduce claustrophobia, they may not be generally accepted for screening. The rates of sedative or anxiolytic medication use were not recorded in this study; however, Murphy and Brunberg (17) reported that 14.3% of consecutive patients required sedation to complete MR imaging. In one study (18), 91% of surveyed respondents who underwent breast MR imaging for local staging or screening reported mild or no discomfort during the examination; however, the patients overestimated the potential

Discussion

For a screening test to be practical, it must be widespread, well tolerated, and cost-effective. Breast MR imaging screening is increasingly becoming available and being used in the United States and Western Europe but is less available in Canada and much less available in South America and Asia. In 2006 in the United States, breast MR imaging was offered at 64% of responding practices among surveyed members of the Society of Breast Imaging, but 31% of practices with MR imaging screening services did not perform MR imaging–guided breast interventional procedures (10). In our protocol, only 14 (70%) of 20 active ACRIN 6666 sites met the technical and experience requirements to perform breast MR imaging, and participation was postponed at two sites until at least three MR imaging–guided biopsies had been completed at each facility.

Although recent guidelines (3,11) recommend annual contrast-enhanced MR imaging in addition to mammography in certain groups of high-risk women, little has been written about patient acceptance of breast MR imaging. The data that do exist are based on prematurely terminated examinations or those that yielded poor image quality: Prior studies have not addressed those women who refuse to even attempt to undergo the MR examination.

Several factors are known to reduce patient acceptance of breast MR imaging and include claustrophobia and the requirement for intravenous contrast material. Rates of claustrophobia and anxiety severe enough to cause premature termination of the MR examination vary according to the type of MR examination, with the highest rates seen in association with brain, head and neck, and upper extremity MR imaging (12). In our series, 13 (2.0%) of 648 women who presented for breast MR imaging could not complete the examination, and three of these cases—0.5% of the women who were actually placed in the MR unit—were due to claustrophobia, similar to the 1.3% rate reported by Eshel et al (12).

Our study provided us with the unusual opportunity to record information regarding women who decline to undergo breast MR examinations. The rate of women reporting claustrophobia as the reason for declining (130 [25.4%] of 512) was very high in our series. In a Netherlands MR imaging screening study (13), lying in the magnet bore was the aspect of breast MR imaging most frequently reported (by 21% of those surveyed) as rather to extremely uncomfortable. Despite this, 44% of women in the Netherlands cohort preferred MR imaging for screening compared with 14% who preferred mammography. This was due in part to the higher percentage of women who reported that they would feel “completely reassured” by a favorable MR imaging result (64.4%) compared with the percentage of women who reportedly would be completely reassured by a favorable mammographic result (40.1%).

Higher rates of claustrophobia have been reported among middle-aged women compared with the rates reported among other demographic groups (14), and a correlation with higher education levels and higher socioeconomic status has been reported (15). Although hypnosis (16) and anxiolytic agents such as lorazepam or diazepam can be used effectively to reduce claustrophobia, they may not be generally accepted for screening. The rates of sedative or anxiolytic medication use were not recorded in this study; however, Murphy and Brunberg (17) reported that 14.3% of consecutive patients required sedation to complete MR imaging. In one study (18), 91% of surveyed respondents who underwent breast MR imaging for local staging or screening reported mild or no discomfort during the examination; however, the patients overestimated the potential
we observed no increase in reports of concern about gadolinium reactions or NSF as the reason for declining participation. No women who participated in the protocol developed NSF.

A good screening test has few false-positive results: Healthy women should not be harmed. Rates of false-positive results influence both the costs and the tolerance for a screening test. With mammographic screening, a recall for additional imaging occurs for an average of 6%–13% of women. Biopsy performed in 3%–6% of women screened and 19%–32% of biopsies revealing cancer (23). The effects of false-positive results on screening compliance vary, with increased compliance or intent to comply in American women (24,25), no difference in compliance among European women, and decreased compliance in Canadian women (24).

In terms of breast MR imaging, recall rates of 11%–12% have been reported with the first screening and have decreased to as low as 2%–7% with subsequent screenings (26,27). In the very high-risk populations studied, biopsy has been recommended for 7%–18% of women on the basis of MR imaging results, and overall, 40% of these biopsies have revealed cancer (1). In our current series, 27 (5.3%) refusals—representing 2.2% of the 1215 women approached for participation—were due to concern about additional biopsies or testing that might be indicated at MR imaging. This concern was probably highlighted by the informed consent process. Essink-Bot et al (13) reported that 5.1% of participants in the Netherlands MR imaging screening cohort were “seriously worried about the scan result”; this worry probably reflected the participants’ fear that cancer might be present and, to a lesser degree, their concern about additional procedures or testing that might be required.

The ACS guidelines recommending supplemental MR imaging screening in women at high risk for breast cancer (3) were widely publicized in March 2007. Anecdotally, we noted improved participation rates after that announcement, and participation in our protocol was more likely among those women who had a very high lifetime risk of breast benefits of MR imaging, and this probably increased their tolerance.

Open-bore MR imaging causes less patient anxiety and claustrophobia than does closed-bore MR imaging (19–21), but the lower field strength with open-bore MR imaging (typically 0.2–1.0 T) often precludes optimal breast MR imaging owing to the reduced signal-to-noise ratio and the lower spatial and temporal resolution. In one recent report (22), 18 (4.5%) of 397 consecutive patients referred for breast MR imaging were unable to undergo the examination owing to claustrophobia (n = 13) or body habitus (n = 3). These women underwent open-bore MR imaging at 0.2 T, and 86% sensitivity was observed (22). Motion-induced artifacts that result in a nondiagnostic breast MR imaging examination are more common among claustrophobic patients. In our series, the images generated from seven (1.1%) of the 648 attempted examinations were deemed unreadable because of motion artifact or failed contrast material injection, and the seven women refused to repeat the examination.

NSF is a rare complication associated with gadolinium-based contrast agents. Midway through our patient accrual period, on May 23, 2007, the Food and Drug Administration requested manufacturers to include a black box warning with all gadolinium-based contrast agents, and the potential risks, including the risk of death, were immediately added to the consent forms for this study. We required participants to meet accepted standards for renal function, with glomerular filtration rate testing performed in the women older than 60 years and in those suspected of having decreased renal function. Although the publicity surrounding the Food and Drug Administration announcement could have discouraged participation in this protocol, after the announcement
cancer and met the ACS criteria for MR imaging screening. Use of models to estimate the risk of genetic mutations that predispose one to breast cancer remains largely the domain of genetic counselors. Primary care physicians have less experience with such calculations and therefore may be reluctant to recommend MR imaging unless it is recommended by a breast specialist. For 47 (9.2%) of the 512 women who declined to participate in our MR substudy, the reason cited was that her primary care provider would not provide a referral or did not believe MR imaging screening was indicated. However, the frequency of this reason decreased after the ACS guidelines were published. Three (0.4%) of the 703 women who initially agreed to participate cancelled for the same reason.

Not all insurers cover contrast-enhanced breast MR imaging, even for women at high risk. In our population of 627 women at intermediate and high risk who completed an MR imaging examination, 62% of the examinations were performed at sites that initially billed the insurance company. For 48% of examinations initially billed to insurance, the site received no payment or only partial payment (less than $500) from insurance, and ACRIN paid the balance (up to $500) to the site. Even when the insurance company and/or ACRIN covered payment for the initial MR imaging examination, additional costs to the health care system and the patient could result from follow-up MR imaging or other testing, including biopsy. Concerns about costs prompted the refusal of 12.1% of the women who declined to participate in our substudy. Uninsured women can be billed well over $2000 for MR imaging, which is clearly prohibitive for a screening test.

Table 2

<table>
<thead>
<tr>
<th>Variable</th>
<th>Adjusted OR in Main Effects Model*</th>
<th>Final Model</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adjusted OR†</td>
<td>z Score†</td>
</tr>
<tr>
<td></td>
<td>p Value†</td>
<td>Standard Error†</td>
</tr>
<tr>
<td>Covariate of interest</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td>0.51 (0.24, 1.10)</td>
<td>0.51 (0.24, 1.10)</td>
</tr>
<tr>
<td>≥25% lifetime risk</td>
<td>1.67 (1.08, 2.60)</td>
<td>1.53 (1.10, 2.12)</td>
</tr>
<tr>
<td>Cancer (Gail or Claus model)†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥2.5% 5-year risk</td>
<td>1.17 (0.76, 1.81)</td>
<td></td>
</tr>
<tr>
<td>Personal history of breast cancer†</td>
<td>1.12 (0.76, 1.64)</td>
<td></td>
</tr>
<tr>
<td>Prior mammography within 14 months of study entry</td>
<td>0.90 (0.68, 1.19)</td>
<td></td>
</tr>
<tr>
<td>Statistical parameter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p</td>
<td>0.15 (0.06, 0.32)</td>
<td>0.15 (0.06, 0.32)</td>
</tr>
<tr>
<td>Log likelihood†</td>
<td>−788.37</td>
<td>−788.89</td>
</tr>
<tr>
<td>C-statistic</td>
<td>0.5594</td>
<td>0.5560</td>
</tr>
</tbody>
</table>

Note.—Results pertain to 1215 women approached for breast MR imaging screening. OR = odds ratio.

* Numbers in parentheses are 95% confidence intervals.
† Covariate represents presence or absence of condition as primary risk factor and not the actual or abbreviated risk score.
‡ P = .79 for comparison of two models at log likelihood ratio testing.

Overall, 19.01% of the main ACRIN 6666 population had a 25% or greater lifetime risk of breast cancer as the main risk factor according to the Gail et al (8) or Claus et al (9) model and thereby met ACS guidelines (3) for MR screening. Another 0.88% had a history of BRCA mutation as the main risk factor, and 0.29% had prior chest, mediastinal, or axillary radiation therapy by age 30 years and at least 8 years earlier as the main risk factor also meeting ACS guidelines (3) for MR imaging. Thus, just over 20% of women in the main ACRIN 6666 protocol met ACS guidelines for high-risk MR imaging screening (3), with the remaining participants meeting the criteria for the intermediate risk category.

Because the lifetime risk of breast cancer decreases with increasing age, we allowed other definitions of risk in the ACRIN 6666 Protocol. A total of 15.08% of the participants in the main ACRIN 6666 Protocol had a 5-year breast cancer risk of at least 2.5% according to the Gail et al model (8); another 8.44% of the women had a 5-year risk of at least 1.7% according to this model and extremely dense breasts. These definitions are not specifically addressed in the current ACS guidelines. Although women with a lifetime risk of breast cancer of at least 20% according to the Gail et al model (8) meet the ACS guidelines, the ACS recommends against using this model to calculate risk because it does not include paternal family history or patient age at diagnosis and cannot be used to predict risk of BRCA mutation. (See online supplement to ACS guidelines [3].) The Claus et al model (9) is among the models recommended by the ACS. (See online supplement to ACS guidelines [3].) Other accepted models used to determine risk for the purposes of MR imaging include the BRCAPRO (28), Tyrer et al (29), and BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) (30,31) models. However, these models were not widely available at the time the original ACRIN 6666 Protocol was designed, and each of these models can yield underestimations of risk in small families that have few relatives with breast or ovarian cancer.
BREAST IMAGING: Elevated Breast Cancer Risk and Refusal for MR Screening

Inconvenience (related to time constraints in 93 cases and to the required travel in 11 cases) was a factor in the refusal to participate for 104 (20.3%) of 512 women. MR imaging scheduling constraints were problematic for another 21 (4.1%) women who declined participation and for 16 (2.3%) of 703 women who initially agreed to undergo MR imaging. During the patient accrual period, many sites began to contact women in advance of their scheduled 24-month mammography and US examinations and to offer scheduling the MR examination for the same day as the 24-month procedures when possible. Despite these efforts, scheduling MR imaging for days 7–14 after the onset of menses can be challenging for perimenopausal women with irregular periods. Women in the main ACRIN 6666 Protocol had already completed three annual screenings with mammography and US and were probably more motivated to participate in the substudy than are many other women who undergo screening. Some women in the main protocol, however, may have been tired of participating in research protocols.

No set dialogue was used to discuss the MR examination with potential participants, although researchers were encouraged to provide summary data from trials that had included both MR imaging and US examinations, in which 93% of cancers had been seen with combined screening with MR imaging and mammography compared to 54% with combined screening with mammography and US (27.32–35). Despite these results, many participants in the main ACRIN 6666 Protocol may have felt secure with their mammography and US results alone or believed that they were “doing enough.”

In summary, in a population of 1215 women at elevated risk of breast cancer who were offered a contrast-enhanced MR imaging screening examination, only 703 (57.3%) agreed. Seventy-five women—representing 6.2% of those asked to participate and 10.7% of those who agreed to participate—did not successfully complete the MR examination, and one did not complete MR imaging within the specified time of 91 days after mammography and US. Thus, only 627 (51.6%) of the women approached for the substudy successfully completed MR imaging screening according to the protocol. The modest rate of participation was due in part to high rates of claustrophobia (over 25%) among the women who declined participation and a lack of perceived benefit on the part of the patient and/or referring physician. Our study results suggest that there may be a large group of women at elevated risk of breast cancer for whom MR imaging would not be acceptable; for these women, supplemental screening with combined US and mammography could be considered, provided the woman is informed of the risk of false-positive results with US screening (6) and the reduced sensitivity for cancer detection compared with the risks of false-positive results and the sensitivity of MR imaging (1).

Acknowledgments: The authors thank the other site investigators and research associates who participated in the MR imaging substudy of ACRIN 6666, specifically A. Thomas Stavros, MD, Radiology Imaging Associates, Denver, Colo; Gary Whltman, MD, University of Texas M. D. Anderson Cancer Center, Houston, Tex; Anne Hoyt, MD, David Geffen School of Medicine at University of California Los Angeles Medical Center, Los Angeles, Calif; William A. Fuller, MD, Allegheny Singer Research Institute, Pittsburgh, Pa; and Marcela Böhm-Vélez, MD, Weinstein Imaging Associates, Pittsburgh, Pa. The authors also thank R. Edward Hendrick, PhD, University of Colorado, Denver, Colo, for assistance with MR image review and site quality control; Mark D. Schleinitz, MD, Brown University, Providence, RI, and Barbara K. LeStage, MPH, for thoughtful review and comments; Cynthia B. Olson, MBA, MBIA, for administrative assistance; and Jean B. Cornack, PhD, Center for Statistical Sciences, Brown University, Providence, RI, for many helpful discussions. W.A.R. is a consultant to Noviscan.

Table 3

| Table 3 | Reasons for Declining or Not Completing Contrast-enhanced Breast MR Screening among Women with Elevated Breast Cancer Risk |

<table>
<thead>
<tr>
<th>Reason</th>
<th>Declined MR Imaging (n = 512)</th>
<th>Initially Agreed to Undergo MR Imaging (n = 703)*</th>
<th>All Women Approached for MR Substudy (n = 1215)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Claustrophobia</td>
<td>130 (25.4)</td>
<td>3 (0.4)</td>
<td>133 (10.9)</td>
</tr>
<tr>
<td>Patient time constraints and/or other priorities</td>
<td>93 (18.2)</td>
<td>NA</td>
<td>93 (7.7)</td>
</tr>
<tr>
<td>Financial concern†</td>
<td>62 (12.1)</td>
<td>7 (1.0)</td>
<td>69 (5.7)</td>
</tr>
<tr>
<td>Physician would not provide referral or did believe MR was indicated</td>
<td>47 (9.2)</td>
<td>3 (0.4)</td>
<td>50 (4.1)</td>
</tr>
<tr>
<td>Patient not interested or did not want to participate</td>
<td>40 (7.8)</td>
<td>NA</td>
<td>40 (3.3)</td>
</tr>
<tr>
<td>Patient could not tolerate MR imaging‡</td>
<td>39 (7.6)</td>
<td>10 (1.4)</td>
<td>49 (4.0)</td>
</tr>
<tr>
<td>Patient did not want to undergo intravenous injection</td>
<td>29 (5.7)</td>
<td>NA</td>
<td>29 (2.4)</td>
</tr>
<tr>
<td>Patient concerned about additional biopsies or testing that MR results might indicate</td>
<td>27 (5.3)</td>
<td>NA</td>
<td>27 (2.2)</td>
</tr>
<tr>
<td>MR imaging scheduling constraints</td>
<td>21 (4.1)</td>
<td>16 (2.3)</td>
<td>37 (3.0)</td>
</tr>
<tr>
<td>Travel-related concern§</td>
<td>11 (2.2)</td>
<td>2 (0.3)</td>
<td>13 (1.1)</td>
</tr>
<tr>
<td>Gadolinium allergy or intolerance of fear of reaction, including NSF</td>
<td>7 (1.4)</td>
<td>NA</td>
<td>7 (0.6)</td>
</tr>
<tr>
<td>Reason unknown</td>
<td>6 (1.2)</td>
<td>NA</td>
<td>6 (0.5)</td>
</tr>
<tr>
<td>Patient did not present for appointment</td>
<td>NA</td>
<td>18 (2.6)</td>
<td>18 (1.5)</td>
</tr>
<tr>
<td>Patient withdrew consent for MR imaging</td>
<td>NA</td>
<td>9 (1.3)</td>
<td>9 (0.7)</td>
</tr>
<tr>
<td>Technically inadequate MR examination, with patient refusal to repeat</td>
<td>NA</td>
<td>7 (1.0)</td>
<td>7 (0.6)</td>
</tr>
<tr>
<td>Total‡</td>
<td>512/1215 (42.1)</td>
<td>75/703 (10.7)</td>
<td>587/1215 (48.3)</td>
</tr>
</tbody>
</table>

Note.—Data are numbers of women. NA = not applicable in given group of women.
* Only a subset of responses was available for recording reasons for not completing MR imaging among the women who agreed to participate in the MR imaging substudy.
† Financial concern included those related to insurance coverage and/or the deductible.
‡ Patient could not tolerate MR imaging owing to pacemaker or other implant, body habitus, and/or frail medical condition.
§ Patient was concerned about the distance required to travel for MR examination and/or the related inconvenience, or patient moved.
∥ One participant underwent MR imaging outside the time frame specified for the study protocol. Thus, a total of 627 participants successfully completed the MR screening examination according to the protocol.
and has received equipment support from Siemens and MediPattern. R.A.J. has a research collaboration with GE Medical Systems. R.G.B. is on the ultrasonography advisory boards of and has received equipment support from Siemens and Philips Ultrasound. The laboratory with which E.D.P. is affiliated receives research support from GE Medical Systems, Sectra, Konica Minolta, and Hologic. W.E.P. is on the scientific advisory board of Hologic. M.C.M. is a consultant to Johnson and Johnson and SonoSite and is on the scientific advisory board of Hologic. E.B.M. is on the scientific advisory boards of Hologic, MediPattern, and Siemens; has received equipment support from Philips Ultrasound, Siemens, and Toshiba Ultrasound and research support from SuperSonic Imagine and Siemens; and is a consultant to Philips Ultrasound. The remaining authors have no financial disclosures.

References